title: Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes.
abstract: Visfatin is an independent association factor for type 2 diabetes mellitus (T2DM). In order to evaluate the plasma visfatin levels and investigate whether plasma visfatin concentrations are altered by intensive glycemic control in patients with diabetes, we determined plasma visfatin concentrations and metabolic parameters in 53 newly diagnosed type 2 diabetic patients and 35 healthy controls. Visfatin levels were also investigated before and after intensive glycemic control for three months in subgroup of patients with T2DM. Plasma visfatin levels were significantly elevated in diabetic patients compared with healthy controls (p<0.001). Circulating visfatin concentration was associated with fasting plasma glucose (FPG), 2-hour OGTT plasma glucose (2hPG), HOMA-beta indexes (r=0.338, p=0.001; r=0.340, p=0.002; r=-0.296, p=0.006, respectively), but not with insulin sensitivity (HOMA-IR) or other metabolic or anthropometric parameters in all subjects. In addition, visfatin levels were also correlated with HbA1c levels in diabetic patients. Furthermore, visfatin concentrations reduced from 25.0+/-6.5 ng/ml at baseline to 20.3+/-4.7 ng/ml (p<0.01) after 3 months of intensive glycemic control, while HbA1c levels decreased from 9.0+/-1.8% to 6.2+/-0.7% (p<0.01). We conclude that the change of visfatin concentration may be a compensatory mechanism to ameliorate insulin deficiency due to pancreatic beta-cell dysfunction.
authors.affiliation: Department of Endocrinology, First Affiliated Hospital, Nanjing Medical University, Nanjing, China.
authors.forename: J
authors.initials: J
authors.lastname: Zhu
authors.forename: M
authors.initials: M
authors.lastname: Schott
authors.forename: R
authors.initials: R
authors.lastname: Liu
authors.forename: C
authors.initials: C
authors.lastname: Liu
authors.forename: B
authors.initials: B
authors.lastname: Shen
authors.forename: Q
authors.initials: Q
authors.lastname: Wang
authors.forename: X
authors.initials: X
authors.lastname: Mao
authors.forename: K
authors.initials: K
authors.lastname: Xu
authors.forename: X
authors.initials: X
authors.lastname: Wu
authors.forename: S
authors.initials: S
authors.lastname: Schinner
authors.forename: C
authors.initials: C
authors.lastname: Papewalis
authors.forename: W A
authors.initials: WA
authors.lastname: Scherbaum
authors.forename: C
authors.initials: C
authors.lastname: Liu
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000032:analysis*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D005215:Fasting; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007328:Insulin / Q000008:administration & dosage / Q000097:blood; D008297:Male; D008875:Middle Aged; D054409:Nicotinamide Phosphoribosyltransferase / Q000097:blood*; D009569:Nitric Oxide / Q000032:analysis; D014280:Triglycerides / Q000097:blood
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D054409:Nicotinamide Phosphoribosyltransferase; D009569:Nitric Oxide; D014280:Triglycerides; C058377:hemoglobin A, glycosylated-nitric oxide complex